The Journal of Precision Medicine
PMLS
PMLS
BMS
BMS

Blueprint Medicines Reports Second Quarter 2022 Results

2022-08-10T21:02:03-05:00August 10th, 2022|

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2022. "We are now one year into the AYVAKIT launch in advanced systemic mastocytosis (SM) and continue to see a significant expansion of our prescriber base as well as strong patient demand, reinforcing [...]

GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution

2022-08-10T20:54:23-05:00August 10th, 2022|

Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution. Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing a [...]

Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests

2022-08-10T20:50:25-05:00August 10th, 2022|

Metabolon, Inc., the global leader in metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests. Metabolon will analyze Mayo Clinic patient clinical samples across multiple cohorts to look for disease biomarkers. New [...]

Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma

2022-08-10T20:46:27-05:00August 10th, 2022|

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced positive topline results from KarMMa-3, a Phase 3, global, randomized, multicenter, open-label study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory after two to four prior lines of therapy and [...]

23andMe Pins Future on ‘Genomic Health Service,’ Therapeutic Development

2022-08-10T20:42:15-05:00August 10th, 2022|

Since its $400 million acquisition of telehealth platform developer and telepharmacy services company Lemonaid Health last November, 23andMe has started expanding beyond its core consumer genetic testing into a new business line called its genomic health service. "Developing our genomic health service for our customers remains a high priority for our consumer business," CFO [...]

Myocardial Infarction Features Found With Multiomic Molecular Map

2022-08-10T20:39:10-05:00August 10th, 2022|

A team from Germany, Slovenia, the Netherlands, UK, and US turned to single-cell gene expression profiling and other omics approaches to put together a "molecular map" of myocardial infarction effects — work that is expected to improve investigators' understanding of the coronary heart condition. With the help of spatial gene expression profiling, single-nucleus RNA [...]

Oncology Business Pushes Invitae’s Q2 Revenues up 18 Percent

2022-08-10T20:31:51-05:00August 10th, 2022|

Invitae reported after the market close on Tuesday that its total second quarter revenues rose almost 18 percent year over year, to $136.6 million, just shy of analysts' estimate of $136.85 million, and driven largely by the company's oncology business. Invitae CFO Roxi Wen said on a conference call after the release of the [...]

10x Genomics Lowers Full-Year 2022 Revenue Guidance by Approximately $100M

2022-08-10T20:27:43-05:00August 10th, 2022|

10x Genomics said on Monday after the close of the market that it is lowering its 2022 revenue guidance by approximately $100 million. The Pleasanton, California-based single-cell and spatial omics analysis technologies firm now expects revenue in the range of $500 million to $520 million, representing growth of 2 percent to 6 percent over [...]

Mass General Program to Help Doctors Balance End-of-Life Talks With Precision Oncology Optimism

2022-07-11T12:37:37-05:00July 11th, 2022|

Researchers at Massachusetts General Hospital are developing a supportive care model to help advanced lung cancer patients better understand their prognosis after research showed that the optimism around precision oncology is making it difficult for oncologists and patients to have more sobering but realistic discussions about end-of-life decisions. The research, led by Laura Petrillo, [...]

Go to Top